Search
Keros Therapeutics Inc
KROSAdd to Watchlist
11.260USD
+0.380+3.49%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
222.19MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.49%
5 Days
+2.46%
1 Month
+4.55%
6 Months
-39.27%
Year to Date
-44.70%
1 Year
-16.28%
Key Figures
10.880Open
11.420High
403.61KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.05%Turnover Ratio
10.880Prev. Close
10.880Low
2.87MTurnover
LossP/E Static
0.78P/B
0.00%Div Yield TTM
-15.53%ROA
22.55052wk High
1.26Volume Ratio
-187.35MNet Profit
19.73MShares
-2.5301EPS TTM
0.95Beta
-16.79%ROE
9.79052wk Low
4.96%Amplitude
100.00%Gross Margin
222.19MMarket Cap
0.37Reward/Risk
2.75%Risk Rate
TradingKey Stock Score of Keros Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Keros Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 97 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.83.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Keros Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Keros Therapeutics Inc Highlights
StrengthsRisks
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 161529.80% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -4.45, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 22.62M shares, decreasing 59.03% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 106.10K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
21.833
Target Price
+100.67%
Upside Space
Keros Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Keros Therapeutics Inc Info
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Ticker SymbolKROS
CompanyKeros Therapeutics Inc
CEOSeehra (Jasbir)
Websitehttps://www.kerostx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Keros Therapeutics Inc (KROS)?
The current price of Keros Therapeutics Inc (KROS) is 11.26.
What is the symbol of Keros Therapeutics Inc?
The ticker symbol of Keros Therapeutics Inc is KROS.
What is the 52-week high of Keros Therapeutics Inc?
The 52-week high of Keros Therapeutics Inc is 22.55.
What is the 52-week low of Keros Therapeutics Inc?
The 52-week low of Keros Therapeutics Inc is 9.79.
What is the market capitalization of Keros Therapeutics Inc?
The market capitalization of Keros Therapeutics Inc is 222.19M.
Is Keros Therapeutics Inc (KROS) currently rated as Buy, Hold, or Sell?
According to analysts, Keros Therapeutics Inc (KROS) has an overall rating of Buy, with a price target of 21.83.
What is the Earnings Per Share (EPS TTM) of Keros Therapeutics Inc (KROS)?
The Earnings Per Share (EPS TTM) of Keros Therapeutics Inc (KROS) is 2.34.